Finally, we investigated (d) whether pentamidine vehiculation by PENVE (5 μmol/L) was able to rescue mucosal pro‐inflammatory markers and pro‐apoptotic factors in order to evaluate whether S100B/wtp53 targeting by PENVE might potentially represent an alternative strategy to the current colon cancer chemotherapy. This evidence concerns the gene S100B and malignant colon neoplasm.